Knowledge Center

Ash Stevens Receives Recognition as a Top Performer in all Categories at the 2016 CMO Leadership Award Ceremony in NYC

Riverview, Michigan, March 29, 2016 – Ash Stevens Inc., a leading provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, is pleased to announce the company recently received recognition at the 2016 CMO (Contract Manufacturing Organization) Leadership Awards Ceremony as an overall top performer in all five core performance categories. The award ceremony took place at the “W” Hotel in New York City on March 16th, 2016. This is the second consecutive year that Ash Stevens has been recognized in all five categories albeit the 2015 results were conducted by a different marketing research and intelligence firm using different criteria methodology.

This year, the five CMO Leadership Award categories included Quality, Reliability, Capabilities, Expertise, and Compatibility. The CMO Leadership Awards are sponsored by the industry leading publication Life Science Leader.  The awards are based on independent market research data provided by the firm Industry Standard Research (IRS) which employs benchmarking methodology to measure actual CMO performance metrics over that of marketing and reputation perceptions.

The 2016 awards also included a new award category that recognizes CMOs that have excelled in one or more of eight “individual attribute” performance categories in the areas of Cultural Fit, State-of-the-Art, Innovation, On-Time, Right-First-Time, Strength of Science, and Reputation.  Ash Stevens received recognition in all eight categories making it a clean sweep for the evening.   

Dr. Stephen Munk, Ash Stevens’ President & CEO said, “It is quite an honor to be recognized for the second consecutive year at the CMO Leadership Awards Ceremony in all five performance categories, particularly when two different marketing research firms and criteria were employed in 2015 and 2016 to do the metrics and both firms independently arrived at similar results.” “This year’s results are based mainly on feedback from respondents who have worked with us in the past 18 months. We welcome their response since customer feedback is our best source for learning and continuous improvement.”

About Ash Stevens Inc.
Ash Stevens Inc. is a full service pharmaceutical Contract Development and Manufacturing Organization (CDMO) offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Riverview, Michigan, Ash Stevens has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for Life Science companies developing innovator small-molecule therapeutics. Ash Stevens is a long-time provider of contract research services to the National Institutes of Health and the National Cancer Institute, and has participated in the development of many important drugs developed through these government agencies. To date, Ash Stevens has received thirteen FDA manufacturing approvals for innovator APIs, including four fast-track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, Clolar® and Iclusig®. Services offered by Ash Stevens include process development and scale-up; cGMP manufacturing; development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing.

For more information, visit www.ashstevens.com or contact Dr. James Hamby, Vice President of Business Development (jhamby@ashstevens.com).